Language Selector:

A trusted team of clinical and engineering experts

Executive Team

Doug Evans
Doug Evans
President and CEO

Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.  

Nawzer Mehta
Nawzer Mehta
SVP Clinical Affairs

Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.  

Judy Ways
Judy Ways
VP Regulatory Affairs

Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.  

Rosemarie Dhavale
Rosemarie Dhavale
VP Finance

Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.  

Matt Gani
Matt Gani
VP Research

Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.  

Viral Thakkar
Viral Thakkar
VP Operations

Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.  

Clinical Board

benditt
Joshua O. Benditt, MD
University of Washington

Matt Gani, Vice President of Operations,

Update new content..has more than 18 years of prior experience in managing and execution of all phases of Medical Device Design and Development from market definition through production and release. Viral has worked in medical device companies, internationally, in projects involving power-actuated surgical stapling devices, cardiovascular and peripheral stents, stent delivery systems, embolic protection

has more than 15 years of prior experience in managing and execution of all phases of Medical Device Design and Development from market definition through production and release. Viral has worked in medical device companies, internationally, in projects involving power-actuated surgical stapling devices, cardiovascular and peripheral stents, stent delivery systems, embolic protection

branson
Rich Branson, MSc, RRT
University of Cincinnati

Matt Gani, Vice President of Operations,

Update new content..has more than 18 years of prior experience in managing and execution of all phases of Medical Device Design and Development from market definition through production and release. Viral has worked in medical device companies, internationally, in projects involving power-actuated surgical stapling devices, cardiovascular and peripheral stents, stent delivery systems, embolic protection

has more than 15 years of prior experience in managing and execution of all phases of Medical Device Design and Development from market definition through production and release. Viral has worked in medical device companies, internationally, in projects involving power-actuated surgical stapling devices, cardiovascular and peripheral stents, stent delivery systems, embolic protection

Dres_Eole
Martin Dres, MD
Sorbonne University

Ralf Ewert

Ralf is awesome!  I can fill in his bio here

has more than 15 years of prior experience in managing and execution of all phases of Medical Device Design and Development from market definition through production and release. Viral has worked in medical device companies, internationally, in projects involving power-actuated surgical stapling devices, cardiovascular and peripheral stents, stent delivery systems, embolic protection

ewert
Ralf Ewert, MD
Universitätsmedizin Greifswald

Ralf Ewert

Ralf is awesome!  I can fill in his bio here

has more than 15 years of prior experience in managing and execution of all phases of Medical Device Design and Development from market definition through production and release. Viral has worked in medical device companies, internationally, in projects involving power-actuated surgical stapling devices, cardiovascular and peripheral stents, stent delivery systems, embolic protection

georgopoulos
Dimitris Georgopoulos, MD, PhD
University of Crete

Matt Gani, Vice President of Operations,

Update new content..has more than 18 years of prior experience in managing and execution of all phases of Medical Device Design and Development from market definition through production and release. Viral has worked in medical device companies, internationally, in projects involving power-actuated surgical stapling devices, cardiovascular and peripheral stents, stent delivery systems, embolic protection

has more than 15 years of prior experience in managing and execution of all phases of Medical Device Design and Development from market definition through production and release. Viral has worked in medical device companies, internationally, in projects involving power-actuated surgical stapling devices, cardiovascular and peripheral stents, stent delivery systems, embolic protection

girard
Timothy D. Girard, MD, MSCI
University of Pittsburgh

Matt Gani, Vice President of Operations,

Update new content..has more than 18 years of prior experience in managing and execution of all phases of Medical Device Design and Development from market definition through production and release. Viral has worked in medical device companies, internationally, in projects involving power-actuated surgical stapling devices, cardiovascular and peripheral stents, stent delivery systems, embolic protection

has more than 15 years of prior experience in managing and execution of all phases of Medical Device Design and Development from market definition through production and release. Viral has worked in medical device companies, internationally, in projects involving power-actuated surgical stapling devices, cardiovascular and peripheral stents, stent delivery systems, embolic protection

goligher
Ewan Goligher, MD, PhD
University of Toronto

Matt Gani, Vice President of Operations,

Update new content..has more than 18 years of prior experience in managing and execution of all phases of Medical Device Design and Development from market definition through production and release. Viral has worked in medical device companies, internationally, in projects involving power-actuated surgical stapling devices, cardiovascular and peripheral stents, stent delivery systems, embolic protection

has more than 15 years of prior experience in managing and execution of all phases of Medical Device Design and Development from market definition through production and release. Viral has worked in medical device companies, internationally, in projects involving power-actuated surgical stapling devices, cardiovascular and peripheral stents, stent delivery systems, embolic protection

dean-hess
Dean Hess, PhD, RRT
Massachusetts General Hospital

Matt Gani, Vice President of Operations,

Update new content..has more than 18 years of prior experience in managing and execution of all phases of Medical Device Design and Development from market definition through production and release. Viral has worked in medical device companies, internationally, in projects involving power-actuated surgical stapling devices, cardiovascular and peripheral stents, stent delivery systems, embolic protection

has more than 15 years of prior experience in managing and execution of all phases of Medical Device Design and Development from market definition through production and release. Viral has worked in medical device companies, internationally, in projects involving power-actuated surgical stapling devices, cardiovascular and peripheral stents, stent delivery systems, embolic protection

hill
Nicholas S. Hill, MD
Tufts University School of Medicine

Matt Gani, Vice President of Operations,

Update new content..has more than 18 years of prior experience in managing and execution of all phases of Medical Device Design and Development from market definition through production and release. Viral has worked in medical device companies, internationally, in projects involving power-actuated surgical stapling devices, cardiovascular and peripheral stents, stent delivery systems, embolic protection

has more than 15 years of prior experience in managing and execution of all phases of Medical Device Design and Development from market definition through production and release. Viral has worked in medical device companies, internationally, in projects involving power-actuated surgical stapling devices, cardiovascular and peripheral stents, stent delivery systems, embolic protection

hyzy
Robert C. Hyzy, MD
University of Michigan

Matt Gani, Vice President of Operations,

Update new content..has more than 18 years of prior experience in managing and execution of all phases of Medical Device Design and Development from market definition through production and release. Viral has worked in medical device companies, internationally, in projects involving power-actuated surgical stapling devices, cardiovascular and peripheral stents, stent delivery systems, embolic protection

has more than 15 years of prior experience in managing and execution of all phases of Medical Device Design and Development from market definition through production and release. Viral has worked in medical device companies, internationally, in projects involving power-actuated surgical stapling devices, cardiovascular and peripheral stents, stent delivery systems, embolic protection

labo
François Lellouche, MD, PhD
Institut Universitaire de Cardiologie et de Pneumologie de Québec

Ralf Ewert

Ralf is awesome!  I can fill in his bio here

has more than 15 years of prior experience in managing and execution of all phases of Medical Device Design and Development from market definition through production and release. Viral has worked in medical device companies, internationally, in projects involving power-actuated surgical stapling devices, cardiovascular and peripheral stents, stent delivery systems, embolic protection

shrager
Joseph B. Shrager, MD
Stanford University School of Medicine

Matt Gani, Vice President of Operations,

Update new content..has more than 18 years of prior experience in managing and execution of all phases of Medical Device Design and Development from market definition through production and release. Viral has worked in medical device companies, internationally, in projects involving power-actuated surgical stapling devices, cardiovascular and peripheral stents, stent delivery systems, embolic protection

has more than 15 years of prior experience in managing and execution of all phases of Medical Device Design and Development from market definition through production and release. Viral has worked in medical device companies, internationally, in projects involving power-actuated surgical stapling devices, cardiovascular and peripheral stents, stent delivery systems, embolic protection

Board of Directors

kiple
Chris Kiple
Chair

Chris Kiple, Chair of the Board of Directors

Chris Kiple is Chair of the Board of Directors at Lungpacer Medical and was formerly the Chief Executive Officer at Ventec Life Systems.  During nearly six years at Ventec, Chris led the company’s transformation from R&D to more than $800M in global sales and 1,000+ team members. 

Chris was part of the original team that developed VOCSN, the world’s first Multi-Function Ventilator that combines six medical devices into a single, portable system.  VOCSN was awarded “Hardware of the Year” by GeekWire, “Best New Technology Solution” by Medtech Breakthrough, and the “Design Award” by Red Dot. 

In response to the global COVID-19 pandemic, Chris developed a first-of-its-kind partnership with General Motors to rapidly scale production of critical care ventilators by 80x in less than six months by bringing the best of American medical device innovation with the best of American automobile mass production capability.  The partnership with General Motors was recognized by Fast Company as one of the “Top 10 Most Innovative Joint Ventures” in 2021 and by the Project Management Institute as one of “2020’s Most Influential Projects.”

Prior to Ventec, Chris worked in finance at J.P. Morgan, in law at Sidley Austin, LLP, and in government affairs at Husch Blackwell, LLP.

Chris was born in Lincoln, NE.  He graduated from The George Washington University with a degree in International Affairs and later received a law degree from The George Washington University Law School in Washington, D.C.  In 2020, Chris was honored as a “40 under 40” award winner by the Puget Sound Business Journal for his leadership. 

Doug Evans
Doug Evans
Board Member

Doug Evans, President and CEO

Doug Evans, PE, President and CEO of Lungpacer Medical Inc., is an accomplished medical device executive, business leader, and strategist with 30 years of industry, public, and private company experience. He is a serial innovator of first-of-their-kind products and has over 200 issued patents covering dozens of devices used by over 15 million patients worldwide, generating greater than $4 billion in end-user sales.

Doug serves as Chairman for TELA Bio (NASDAQ: TELA) and Board Member for WhiteSwell Medical.  Previously Doug served as Operating Director, Secretary, and Board Member of Intact Vascular (acquired by Royal Philips for $360M in 2020); as advisor to Essential Medical (acquired by Teleflex in 2018); and as Chief Operating Officer and Board Member of Kensey Nash Corporation (NASDAQ: KNSY) (acquired by Royal DSM for $360M in 2012).
 
Doug has a Bachelors in Engineering Science, an honors degree in Bioengineering, and a Masters in Business Management from Pennsylvania State University, as well as a Masters in Electrical Engineering from University of Pennsylvania.
 
Doug is the co-founder of Cure4Cam Childhood Cancer Foundation, which seeks to raise community awareness about childhood cancers and supports the development of new and more humane therapies for children.
Jose Pepe Calle Gordo
Jose Calle Gordo
Board Member

Jose (Pepe) Calle Gordo, Board Member

Jose (Pepe) Calle Gordo is an operating partner at Valiance, a venture growth investment firm in London, chairman at Highlife, a structural heart company, and board member at several med tech companies.

Before that, he served as CEO of Biosensors International, an interventional cardiology company.  Previously he held several leadership roles at Abbott Vascular and Guidant in the fields of coronary intervention, structural heart, peripheral vascular and cardiac resynchronization therapy.  Jose started his career at Eli Lilly where he held a number of commercial roles with growing responsibility in the field of cardiac rhythm management devices.

Josh Makower
Josh Makower
Board Member

Josh Makower, Board Member

Josh Makower, MD has served on the board of Lungpacer Medical since 2019 and is a Special Partner on NEA’s healthcare team. In addition to his role at NEA, Josh serves on the faculty of the Stanford University Medical and Engineering Schools as a Professor of Medicine and Bioengineering and is Director and Co-Founder of The Stanford Byers Center for Biodesign. Josh is also the Founder and Executive Chairman of ExploraMed, a medical device incubator that has created 9 companies over the past 25 years. Notable transactions from the ExploraMed portfolio include Acclarent, acquired by J&J in 2009, EndoMatrix, acquired by C.R. Bard in 1997, TransVascular, acquired by Medtronic in 2003, Nuelle, acquired by AyTu Biosciences in 2014, and Neotract acquired by Teleflex in 2017. On-going ExploraMed/NEA ventures include Moximed, Willow Innovations, Revelle Aesthetics, and ExploraMed V. Josh currently serves on the boards of Eargo, Allay Therapeutics, Lungpacer, Revelle Aesthetics, Vesper Medical, Magenta Medical, DOTS Technology Corp., ExploraMed, Intrinsic Therapeutics, Moximed, SetPoint Medical, Willow and Coravin. 

Josh holds over 300 patents and patent applications for various medical devices in the fields of cardiology, ENT, general surgery, drug delivery, obesity, orthopedics, women’s health, aesthetics, and urology. He received an MBA from Columbia University, an MD from the NYU School of Medicine, and a bachelor’s degree in Mechanical Engineering from MIT, and is a Fellow of the American Institute of Biomedical Engineering and a member of the National Academy of Engineering.

Joseph Kaufmann
Joseph Kaufmann
Board Member

Joseph Kaufmann, Board Member

Joseph Kaufmann, is an Investment Manager at 4CGE LLC, a US based investment group that is the largest shareholder in Lungpacer. Joe was an early investor and served as the Chairman of the Board of privately held Essential Medical a startup medical device company specializing in large bore vascular closure products.  Essential Medical had a successful exit with the sale of the company to Teleflex in 2018. 
 

Previous experience as  President and CEO of Kensey Nash Corporation (NASDAQ – KNSY) from 1995 to 2012 and CFO from 1989 to 1995.  Kensey Nash was a leader in vascular closure, orthopedic/spine devices and resorbable biomaterial products. The company was sold to Royal DSM for $360M in 2012.

Graduated from St. Joseph’s University B.S. Accounting in 1975.

KarenLong_WhiteBackground_600x748
Karen Long
Board Member

Karen Long, Board Member

Update new content. Update new content. Update new content. Update new content. Update new content. Update new content. Update new content. Update new content. Update new content. Update new content. Update new content. Update new content. Update new content. Update new content. 

 

Update new content. Update new content. 

Bob Donohue
Bob Donohue
Board Member

Bob Donohue, Board Member

Robert (Bob) Donohue is the CEO of WJFS, Inc., a private investment group based in West Chester, PA.  Bob also sits on the board of two privately held companies Centinel Spine, AES Clean Technology as well as the nonprofit LOR Foundation.

Prior to WJFS, Bob held the position of CFO of Synthes, Inc. where he was responsible for the Company’s financial reporting, internal controls, M&A, and related issues. He also held the position of President, Synthes Canada, Ltd from 1997 until the sale of the company in mid – 2012.  Bob remained with the company, to assist with integration, for 18 months after its sale to J&J in 2012 ($20 Billion). Bob started with Synthes in 1990 as Corporate Controller.  Prior to joining the Synthes, he served in several financial positions, including corporate controller and plant controller with several major U.S. corporations.

Education: B.Sc. in Economics, West Chester University; MBA, Widener University. Certified Public Accountant (inactive).

Key Milestones

2015

First human use of Lungpacer Diaphragm Pacing System.

2016

FDA designates Lungpacer as a "Breakthrough Device." RESCUE 1 Clinical Study begins.

2017

RESCUE 2 Clinical Study begins.

2018

US team and operations start.

2019

RESCUE 3 Clinical Study begins.

2020
FDA Approval of Emergency Use Authorization to support COVID-19 Pandemic response.*

Lungpacer Patents

Large and growing intellectual property portfolio

Learn more about Lungpacer’s patent portfolio

Awards

Emergency Use Authorization. The Lungpacer System is authorized for emergency use in healthcare settings to assist in weaning patients determined by their healthcare provider to be at high risk of weaning failure off ventilators during the COVID-19 pandemicThe Lungpacer System has neither been cleared nor approved for the indication to assist in weaning patients off ventilators in healthcare settings during the COVID-19 pandemic; the Lungpacer System has been authorized for the above emergency use by FDA under an EUA; the Lungpacer System has been authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of medical devices under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Doug Evans

Doug Evans, President and CEO

Doug Evans, PE, President and CEO of Lungpacer Medical Inc., is an accomplished medical device executive, business leader, and strategist with 30 years of industry, public, and private company experience. He is a serial innovator of first-of-their-kind products and has over 200 issued patents covering dozens of devices used by over 15 million patients worldwide, generating greater than $4 billion in end-user sales.

Doug serves as Chairman for TELA Bio (NASDAQ: TELA) and Board Member for WhiteSwell Medical.  Previously Doug served as Operating Director, Secretary, and Board Member of Intact Vascular (acquired by Royal Philips for $360M in 2020); as advisor to Essential Medical (acquired by Teleflex in 2018); and as Chief Operating Officer and Board Member of Kensey Nash Corporation (NASDAQ: KNSY) (acquired by Royal DSM for $360M in 2012).
 
Doug has a Bachelors in Engineering Science, an honors degree in Bioengineering, and a Masters in Business Management from Pennsylvania State University, as well as a Masters in Electrical Engineering from University of Pennsylvania.
 
Doug is the co-founder of Cure4Cam Childhood Cancer Foundation, which seeks to raise community awareness about childhood cancers and supports the development of new and more humane therapies for children.
Nawzer Mehta

Nawzer Mehta, Senior Vice President of Clinical Affairs

Dr. Nawzer Mehta, Senior Vice President of Clinical Affairs, has held leadership positions in clinical research and product development with Spiration/Olympus Respiratory, Cardiac Dimensions, Northstar Neuroscience, Medtronic and Biotronik. Most recently, he successfully gained pre market approval of the Spiration Valve System for patients with emphysema. 

Dr. Mehta earned a PhD in applied cardiovascular physiology from the University of London and a Bachelor of Science degree in human biology from the University of Surrey.

Judy Ways

Judy Ways, Vice President of Regulatory Affairs

Judy Ways, PhD, Vice President of Regulatory Affairs, has 30 years of regulatory and quality experience in the areas of respiratory, inflammation, and neurology.  She has a strong track record for US and worldwide approvals for first-in-kind devices. She was previously VP Regulatory at Neuronetics, Neuron Therapeutics and MedImmune, and in leadership roles at Aventis Behring and Glaxo. 

Judy obtained her PhD in Immunology and Cancer Biology from Stanford University.

Rosemarie Dhavale

Rosemarie Dhavale, Vice President of Finance

Rosemarie Dhavale, CPA, MBA, Vice President of Finance, has twenty-five years of accounting and finance experience. Ms. Dhavale previously was the Vice President of Finance at Delta Dental of Minnesota and was Senior Director of Finance at Kensey Nash Corporation, a medical device company (acquired by Royal DSM). 

She has been actively involved in analyzing new technologies and businesses throughout her career and lead accounting and finance teams in FP&A, implementations of systems and strategic initiatives.

Matt Gani

Matt Gani, Vice President of Research

Matt Gani, Vice President of Research, has over 25 years of experience leading medical product development projects involving electrical stimulation, pacemaker, and defibrillator devices. 

Matt previously served as the VP of Product Development for Northstar Neuroscience, a developer of cortical stimulation therapies, as the Senior Director for Biotronik, and as PM for Telectronics Pacing Systems, acquired by St. Jude Medical.

Viral Thakkar

Viral Thakkar, Vice President of Operations

Viral Thakkar, Vice President of Operations, has more than 15 years of prior experience in managing and execution of all phases of Medical Device Design and Development from market definition through production and release. Viral has worked in medical device companies, internationally, in projects involving power-actuated surgical stapling devices, cardiovascular and peripheral stents, stent delivery systems, embolic protection devices, catheter based intra-vascular temperature management devices.

Previously, Viral has served in leadership roles for ZOLL, Boston Scientific, Radiant Medical, SMTPL & Power Medical Interventions.

Chris Kiple, Chair of the Board of Directors

Chris Kiple is Chair of the Board of Directors at Lungpacer Medical and was formerly the Chief Executive Officer at Ventec Life Systems.  During nearly six years at Ventec, Chris led the company’s transformation from R&D to more than $800M in global sales and 1,000+ team members. 

Chris was part of the original team that developed VOCSN, the world’s first Multi-Function Ventilator that combines six medical devices into a single, portable system.  VOCSN was awarded “Hardware of the Year” by GeekWire, “Best New Technology Solution” by Medtech Breakthrough, and the “Design Award” by Red Dot. 

In response to the global COVID-19 pandemic, Chris developed a first-of-its-kind partnership with General Motors to rapidly scale production of critical care ventilators by 80x in less than six months by bringing the best of American medical device innovation with the best of American automobile mass production capability.  The partnership with General Motors was recognized by Fast Company as one of the “Top 10 Most Innovative Joint Ventures” in 2021 and by the Project Management Institute as one of “2020’s Most Influential Projects.”

Prior to Ventec, Chris worked in finance at J.P. Morgan, in law at Sidley Austin, LLP, and in government affairs at Husch Blackwell, LLP.

Chris was born in Lincoln, NE.  He graduated from The George Washington University with a degree in International Affairs and later received a law degree from The George Washington University Law School in Washington, D.C.  In 2020, Chris was honored as a “40 under 40” award winner by the Puget Sound Business Journal for his leadership. 

Jose Pepe Calle Gordo

Jose (Pepe) Calle Gordo, Board Member

Jose (Pepe) Calle Gordo is an operating partner at Valiance, a venture growth investment firm in London, chairman at Highlife, a structural heart company, and board member at several med tech companies.

Before that, he served as CEO of Biosensors International, an interventional cardiology company.  Previously he held several leadership roles at Abbott Vascular and Guidant in the fields of coronary intervention, structural heart, peripheral vascular and cardiac resynchronization therapy.  Jose started his career at Eli Lilly where he held a number of commercial roles with growing responsibility in the field of cardiac rhythm management devices.

Josh Makower

Josh Makower, Board Member

Josh Makower, MD has served on the board of Lungpacer Medical since 2019 and is a Special Partner on NEA’s healthcare team. In addition to his role at NEA, Josh serves on the faculty of the Stanford University Medical and Engineering Schools as a Professor of Medicine and Bioengineering and is Director and Co-Founder of The Stanford Byers Center for Biodesign. Josh is also the Founder and Executive Chairman of ExploraMed, a medical device incubator that has created 9 companies over the past 25 years. Notable transactions from the ExploraMed portfolio include Acclarent, acquired by J&J in 2009, EndoMatrix, acquired by C.R. Bard in 1997, TransVascular, acquired by Medtronic in 2003, Nuelle, acquired by AyTu Biosciences in 2014, and Neotract acquired by Teleflex in 2017. On-going ExploraMed/NEA ventures include Moximed, Willow Innovations, Revelle Aesthetics, and ExploraMed V. Josh currently serves on the boards of Eargo, Allay Therapeutics, Lungpacer, Revelle Aesthetics, Vesper Medical, Magenta Medical, DOTS Technology Corp., ExploraMed, Intrinsic Therapeutics, Moximed, SetPoint Medical, Willow and Coravin. 

Josh holds over 300 patents and patent applications for various medical devices in the fields of cardiology, ENT, general surgery, drug delivery, obesity, orthopedics, women’s health, aesthetics, and urology. He received an MBA from Columbia University, an MD from the NYU School of Medicine, and a bachelor’s degree in Mechanical Engineering from MIT, and is a Fellow of the American Institute of Biomedical Engineering and a member of the National Academy of Engineering.

Joseph Kaufmann

Joseph Kaufmann, Board Member

Joseph Kaufmann, is an Investment Manager at 4CGE LLC, a US based investment group that is the largest shareholder in Lungpacer. Joe was an early investor and served as the Chairman of the Board of privately held Essential Medical a startup medical device company specializing in large bore vascular closure products.  Essential Medical had a successful exit with the sale of the company to Teleflex in 2018. 
 

Previous experience as  President and CEO of Kensey Nash Corporation (NASDAQ – KNSY) from 1995 to 2012 and CFO from 1989 to 1995.  Kensey Nash was a leader in vascular closure, orthopedic/spine devices and resorbable biomaterial products. The company was sold to Royal DSM for $360M in 2012.

Graduated from St. Joseph’s University B.S. Accounting in 1975.

KarenLong_WhiteBackground_600x748

Karen Long, Board Member

Ms. Long is the Managing Director of KCK MedTech. KCK focuses capital investment on highly disruptive therapies within the medical device sector. Ms. Long has been with KCK since January 2018 when she joined as Executive-in-Residence. Within KCK, she serves as Board Director at Revelle Aesthetics, Candesant BioMedical, LungPacer Medical, and Barologics, as well as Chairman of the Board of Aerin Medical and Sonex Health. Prior to KCK, Ms. Long was President and CEO of Nuelle, a women’s consumer health company incubated at ExploraMed beginning in 2012. Nuelle was acquired in 2017 by Aytu. In early 2007, she joined Acclarent as Worldwide Vice President of Marketing. Acclarent was acquired in late 2010 by Johnson & Johnson. She remained with J&J until 2012 when she left to join Nuelle. Acclarent was also an early spinout from ExploraMed. Ms. Long has spent over 20 years in medical devices and diagnostics developing and marketing novel and market-leading products focused on improving quality of life. She held a series of key operating roles in ChemTrak and Inverness Medical, and management positions at LifeScan after the acquisition of Inverness Medical by J&J. Ms. Long began her career as a Licensed Clinical Social Worker after receiving her undergraduate and graduate degrees from San Diego State University.
Bob Donohue

Bob Donohue, Board Member

Robert (Bob) Donohue is the CEO of WJFS, Inc., a private investment group based in West Chester, PA.  Bob also sits on the board of two privately held companies Centinel Spine, AES Clean Technology as well as the nonprofit LOR Foundation.

Prior to WJFS, Bob held the position of CFO of Synthes, Inc. where he was responsible for the Company’s financial reporting, internal controls, M&A, and related issues. He also held the position of President, Synthes Canada, Ltd from 1997 until the sale of the company in mid – 2012.  Bob remained with the company, to assist with integration, for 18 months after its sale to J&J in 2012 ($20 Billion). Bob started with Synthes in 1990 as Corporate Controller.  Prior to joining the Synthes, he served in several financial positions, including corporate controller and plant controller with several major U.S. corporations.

Education: B.Sc. in Economics, West Chester University; MBA, Widener University. Certified Public Accountant (inactive).

Dawn Bitz, VP Clinical Development & Marketing

20 years of experience with med device commercialization with Vyaire, Covidien, Boston Scientific, UCB Pharma.